Evidence map›Paper›PMID 28258356›Full record

Observational studyEuropean journal of clinical pharmacology2017

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.

B E Oortgiesen, E N van Roon, P Joosten, R E Kibbelaar, H Storm, S Hovenga, B van Rees, G Woolthuis, N Veeger, E G de Waal and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

B E OortgiesenDepartment of Clinical Pharmacy & Pharmacology, Medical Centre Leeuwarden, Leeuwarden, PO Box 888, 8901 BR Leeuwarden, The Netherlands. Berdien.Oortgiesen@znb.nl.
E N van RoonDepartment of Clinical Pharmacy & Pharmacology, Medical Centre Leeuwarden, Leeuwarden, PO Box 888, 8901 BR Leeuwarden, The Netherlands.
P JoostenDepartment of Haematology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
R E KibbelaarDepartment of Pathology, Pathology Friesland, Leeuwarden, The Netherlands.
H StormDepartment of Clinical Chemistry, Medical Centre Leeuwarden CERTE KCL, Leeuwarden, The Netherlands.
S HovengaDepartment of Haematology, Nij Smellinghe, Drachten, The Netherlands.
B van ReesDepartment of Haematology, Antonius Hospital, Sneek, The Netherlands.
G WoolthuisDepartment of Haematology, Tjongerschans, Heerenveen, The Netherlands.
N VeegerDepartment of Epidemiology, MCL Academy, Leeuwarden, The Netherlands.
E G de WaalDepartment of Haematology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
M HoogendoornDepartment of Haematology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis prospective, observational population-based cohort study was performed to determine overall survival (OS) in multiple myeloma (MM) patients in Friesland, the Netherlands, in the era of novel agents and to analyse the influence of first-line treatment, MM-related end-organ damage and comorbidities at initial presentation on OS.

methodsDetailed clinical information was obtained from the population-based registry 'HemoBase' during the period January 2005 to January 2013, with a follow-up to January 2014.

resultsOverall, the symptomatic MM patients (n = 225) had a median OS of 40 months. In the age categories <65, 65-75 and ≥75 years, 99, 94 and 87% of the patients received treatment, with a median OS of 92, 42 and 31 months, respectively. OS for patients with or without treatment was 43 and 3 months, respectively. In multivariable analysis, risk factors for worse OS were increasing age (<65: reference; 65-75: HR

conclusionsIncreasing age, not receiving initial treatment, hypercalcaemia and impaired renal function at initial presentation were independent risk factors for worse OS. Comorbidity according to Charlson comorbidity index score was not an independent variable predicting OS.

Indexed as

AdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsCohort StudiesFemaleFollow-Up StudiesHumansHypercalcemiaKidney DiseasesMaleMiddle AgedMultiple MyelomaMultivariate AnalysisNetherlandsAntineoplastic AgentsClinical parametersMultiple myelomaNovel agentsOverall survivalPopulation-based registry

Identifiers

PMID28258356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.